Eli Lilly has reported that its interleukin-13 (IL-13) inhibitor Ebglyss (lebrikizumab-lbkz) showed sustained skin clearance ...
Zacks Investment Research on MSN
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
Eli Lilly LLY has been on an acquisition spree since the beginning of this year to bolster its pipeline, which should drive ...
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...
CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...
The Institute for Clinical and Economic Review (ICER) has updated its assessment of the value of Novo Nordisk’s (NOV: N) ...
We came across a bullish thesis on Eli Lilly and Company on Kontra Investments’s Substack by Kontra. In this article, we will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback